Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Surf Air Mobility Inc. (NYSE: SRFM) (the "Company"), a leading regional air mobility platform, closed on the previously announced purchase and sale of 2,000,000 shares of common stock (or pre-funded ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.